GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Equity-to-Asset

Knight Therapeutics (TSX:GUD) Equity-to-Asset : 0.79 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Knight Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$746.9 Mil. Knight Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was C$945.5 Mil. Therefore, Knight Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.79.

The historical rank and industry rank for Knight Therapeutics's Equity-to-Asset or its related term are showing as below:

TSX:GUD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.62   Med: 0.92   Max: 0.99
Current: 0.79

During the past 11 years, the highest Equity to Asset Ratio of Knight Therapeutics was 0.99. The lowest was 0.62. And the median was 0.92.

TSX:GUD's Equity-to-Asset is ranked better than
80.15% of 1088 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs TSX:GUD: 0.79

Knight Therapeutics Equity-to-Asset Historical Data

The historical data trend for Knight Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Equity-to-Asset Chart

Knight Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.62 0.85 0.85 0.78 0.79

Knight Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.78 0.80 0.81 0.79

Competitive Comparison of Knight Therapeutics's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Equity-to-Asset falls into.



Knight Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Knight Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=746.871/945.493
=0.79

Knight Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=746.871/945.493
=0.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Knight Therapeutics  (TSX:GUD) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Knight Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics (TSX:GUD) Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.
Executives
Sime Armoyan 10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines